- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06310512
Efficacy of Pharmacist Interventions Through the "Medication Therapy Management Pathway in Hypertensive Patients" (PharmMTMH)
Efficacy of Pharmacist Interventions Through the "Medication Therapy Management Pathway in Hypertensive Patients":A Prospective, Multicenter, Randomized, Controlled Study
The goal of this Randomized Controlled Trial is to carry out in adult patients with primary hypertension whose blood pressure control is not up to standard. The main question it aims to answer are:
To explore the effect of pharmacists' implementation of "the medication therapy management pathway in hypertensive patients"on the patients with hypertension.
Participants will receive structured drug treatment management at the first diagnosis. During on-site follow-up in the first, third and sixth months, as well as telephone follow-up in the second week, second and fourth months, patients will be evaluated, corresponding information will be collected and possible interventions will be taken.
Researchers will compare the non intervention group to see if patients' blood pressure will also be reduced without intervention.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: JuanJuan Wei, MS
- Phone Number: 01064456609
- Email: weijj2005@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100029
- Beijing Anzhen Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years old, male or female;
- Outpatients diagnosed with primary hypertension who have not received treatment or are receiving antihypertensive medication;
- Mild to moderate hypertensive patients with substandard blood pressure: home blood pressure >140/90 mmHg at least once in the last month or more, and the average sitting blood pressure in the clinic on the day of enrollment is >140/90 mmHg;
- Expected survival > 12 months;
- Voluntary participation in the trial and signing the informed consent form.
Exclusion Criteria:
- Severe hypertension (mean SBP ≥180mmHg, or mean DBP ≥110mmHg), hypertensive emergency or hypertensive sub-emergency (systolic blood pressure >180 mmHg or diastolic blood pressure >120 mmHg);
- Have a history or diagnosis of secondary hypertension, including but not limited to the following: renal hypertension, renal vascular hypertension, aortic stenosis, pheochromocytoma, Cushing's syndrome, cystic nephropathy, etc., but drug-induced hypertension is not an exclusion criterion;
- Patients in the acute stage of the disease requiring emergency medical consultation;
- patients with mental disorder, hearing impairment, intellectual disability, aphasia, etc., resulting in the inability to communicate or to comply with the study agreement
- Patients with tumors;
- Any other reasons that the investigator considers unsuitable for participation in the clinical trial that may affect the efficacy and safety evaluation of the study (including, but not limited to, the investigator's judgment that the subject lives far away and cannot be followed up as scheduled).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group
Intervention group patients will undergo structured drug treatment management at their first visit.
During on-site follow-up at 1, 3, and 6 months, as well as telephone follow-up at the second week, 2 and 4 months, the patient's condition will be evaluated, corresponding information will be collected, and possible intervention measures will be taken for the patient.
|
Interventions mainly included (1) information collection, clinical assessment, and evaluation of medication regimens; (2) identification of and intervention for medication-related problems; (3) pharmacy instruction and education, and development of personal medication lists; and (4) follow-up and reassessment
|
No Intervention: Non-Intervention group
For non intervention group patients, pharmacists evaluate the patient's condition and collect corresponding information at the first visit and on-site follow-up at 1, 3, and 6 months, explain the dosage and dosage of drugs to the patient, and remind them of medication contraindications.
Necessary intervention measures are taken at the 6th month.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
systolic blood pressure
Time Frame: 6 months
|
Change from baseline in mean seated systolic blood pressure at 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
diastolic blood pressure
Time Frame: 6 months
|
Changes from baseline in mean seated diastolic blood pressure at 6 months
|
6 months
|
Change from baseline in mean sitting systolic blood pressure at 3 months
Time Frame: 3 months
|
Change from baseline in mean sitting systolic blood pressure at 3 months
|
3 months
|
Change from baseline in number of medication-related problems (MRP) at 6 months
Time Frame: 6 months
|
Change from baseline in number of medication-related problems (MRP) at 6 months
|
6 months
|
Average number of medication-related problems (MRP) resolved after 6 months
Time Frame: 6 months
|
Average number of medication-related problems (MRP) resolved after 6 months
|
6 months
|
The compliance rate of blood pressure after 6 months
Time Frame: 6 months
|
The compliance rate of blood pressure after 6 months
|
6 months
|
Effective rate of blood pressure lowering after 6 months
Time Frame: 6 months
|
Effective rate of blood pressure lowering after 6 months
|
6 months
|
Time to BP Attainment in Intervention and Non-Intervention Groups
Time Frame: From the date of enrollment to the date when the patient's first blood pressure meets the standard, the evaluation is conducted up to 6 months
|
Time to BP Attainment in Intervention and Non-Intervention Groups
|
From the date of enrollment to the date when the patient's first blood pressure meets the standard, the evaluation is conducted up to 6 months
|
Changes from baseline in adherence scores at 6 months,the General Medication Compliance Scale (GMAS) was used.
Time Frame: 6 months
|
The General Medication Compliance Scale (GMAS) was used, with a maximum score of 33 and a minimum score of 0. The higher the score, the higher the patient's compliance.
|
6 months
|
Economic indicators,mainly including the cost of implementing intervention measures and the impact of intervention measures on patient diagnosis and treatment costs
Time Frame: 6 months
|
The implementation costs of intervention measures mainly include the development, installation, and annual maintenance costs of Interactive Network Response System (IWRS), labor costs of intervention measures, material costs incurred during the intervention process, multi center collaboration costs, and other costs incurred due to the intervention measures.
Intervention measures have an impact on patient diagnosis and treatment costs, mainly including an increase in per visit outpatient expenses and medication costs.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Yang Lin, Beijing Anzhen Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ANZHEN HOSPITOL-LY-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Structured drug therapy management
-
University of Louisiana MonroeOchsner Health SystemCompletedHypertension | Blood PressureUnited States
-
Camden and Islington NHS TrustCompletedPersonality DisordersUnited Kingdom
-
University Children's Hospital, ZurichUniversity of ZurichWithdrawnMuscular Dystrophies
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Institut Catala de SalutUnknownChronic Obstructive Pulmonary DiseaseSpain
-
University of FloridaUS Department of Veterans Affairs; Philips RespironicsCompleted
-
PictureRx, LLCNational Institute on Minority Health and Health Disparities (NIMHD)CompletedUnderstanding of Medication Instructions | Recall of Medication InstructionsUnited States
-
University Hospital, AkershusTerminatedBipolar Disorder | Psychosis | Other Diagnoses and ConditionsNorway
-
University of California, Los AngelesVA Greater Los Angeles Healthcare SystemWithdrawnPTSD | Recent Era Combat Veteran | Couples CommunicationUnited States
-
University of TennesseeWithdrawnOccupational/Physical Therapy | Post-operative Breast ReconstructionUnited States
-
Istanbul University - Cerrahpasa (IUC)Saglik Bilimleri UniversitesiCompletedEducation | Nursing | Pandemics | Crisis StateTurkey